Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Timolol Clear all
Completed Phase 4 Interventional Results available

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

NCT00811850
View directory record Official record
Conditions
Glaucoma
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
30 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 2, 2026, 8:45 PM EDT
Terminated Phase 1 Interventional

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376
View directory record Official record
Conditions
Sturge Weber Syndrome, Port-wine Mark
Interventions
Timolol, Preservative free artificial tear gel.
Drug
Lead sponsor
Wills Eye
Other
Eligibility
2 Years to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 2, 2026, 8:45 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 2, 2026, 8:45 PM EDT
Terminated Phase 1 Interventional

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

NCT01434849
View directory record Official record
Conditions
Infantile Hemangioma, Very Low Birth Weight Infants
Interventions
topical 0.5% Timolol maleate, Control (placebo) group
Drug
Lead sponsor
Alice K. Gong
Other
Eligibility
Up to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 2, 2026, 8:45 PM EDT
Not yet recruiting Phase 2 Interventional

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

NCT07583862
View directory record Official record
Conditions
Surgical Wounds, Mohs Surgery
Interventions
Topical Timolol, Normal Saline
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332345
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
53
States / cities
Anaheim, California • Sacramento, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 2, 2026, 8:45 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

NCT04178863
View directory record Official record
Conditions
Glaucoma; Drugs
Interventions
CATS Tonometer, Latanoprost
Device · Drug
Lead sponsor
Intuor Technologies, Inc.
Industry
Eligibility
18 Years to 101 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Results available

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

NCT00735449
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

NCT00051155
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Results available

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 2, 2026, 8:45 PM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 8:45 PM EDT
Withdrawn Phase 3 Interventional

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

NCT00787436
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Portal Hypertension
Interventions
Thalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

NCT03519386
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Glaucoma Biomarkers

NCT01677507
View directory record Official record
Conditions
Glaucoma, Healthy
Interventions
Variation in eye pressure response to timolol and latanoprost treatment
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Beta Adrenergic Antagonist for the Healing of Chronic DFU

NCT03282981
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions
Timolol, Non biologically active gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 2, 2026, 8:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The International Collaborative Exfoliation Syndrome Treatment Study

NCT00804115
View directory record Official record
Conditions
Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or Cosopt
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2008 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

NCT00716859
View directory record Official record
Conditions
Glaucoma
Interventions
Timolol, latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
36 Weeks to 18 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 2, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 2, 2026, 8:45 PM EDT